Trial reportTransplantation and cellular therapy2026
Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes.
Trial report in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
backgroundA myeloablative busulfan (Bu) and fludarabine (Flu) regimen that includes fractionating Bu and extending its delivery time results in low toxicity, permitting its use in stem cell transplantation recipients who otherwise would receive reduced-intensity conditioning. Cladribine (Clad) is an active agent in acute myeloid leukemia (AML) that may synergize with Flu. This phase 2 randomized trial examined whether additional Bu fractionation improved the efficacy and safety of a Clad- and Flu-containing regimen. STUDY
designPatients with AML or myelodysplastic syndrome (MDS) age 18 to 70 years with a matched donor were randomized to 2 arms. Patients in arm A received outpatient Bu 80 mg/m
resultsA total of 116 patients were randomized, including 59 to arm A and 57 to arm B. The 3-year PFS was 48.7% (95% confidence interval [CI], 37.4% to 63.4%) in arm A and 61.3% (95% CI, 49.9% to 75.4%) in arm B (P = .19). The rate of grade ≥3 toxicities was higher in arm A compared with arm B (93.2% versus 73.7%; P = .005). Three-year nonrelapse mortality in the 2 groups was 19% (95% CI, 8.7% to 29.2%) and 7% (95% CI, 0.3% to 13.7%) (P = .066), and the 3-year relapse rate was 32.3% (95% CI, 20.2% to 44.4%) and 31.7% (95% CI, 19.4% to 43.9%) (P = .99). A multivariate Bayesian regression analysis supported an overall survival and PFS benefit in the longer-duration arm B.
conclusionsThis Bu, Flu, and Clad regimen with 3 weeks of busulfan fractionation appears to be safe and effective. Furthermore, fractionation of Bu with administration over a 3-week period reduces toxicity without increasing the relapse rate, allowing safe delivery of a myeloablative regimen to older patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.